Component
NO availability markers in peripheral arterial disease
Study-scoped entity; inspect species, exposure and experimental limitations on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Plasma arginine rose, but NO-related measurements were reduced or unimproved versus placebo.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- NO-PAIN: 133 PAD patients, 3 g/day for six months.
- limitations
- Endpoint-dependent pattern; not every marker necessarily decreased.
- nutrient_topic
- L-Arginine collection; tissue, species, dose and formulation distinctions retained. · L-Arginine
- plain_language
- Higher blood availability did not ensure better pathway output.
- primary_references
- L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. · 2007 · https://pubmed.ncbi.nlm.nih.gov/17592080/ · DOI 10.1161/circulationaha.106.683656
L-Arginine: transport, metabolic branches, nutrient interactions, availability and discovery questions (2026-09-18) · lines 390–396
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · NO-PAIN: 133 PAD patients, 3 g/day for six months. · source_derived_draft · unverified_draft
## arg-pad-markers Higher blood availability did not ensure better pathway output. Plasma arginine rose, but NO-related measurements were reduced or unimproved versus placebo. Model: NO-PAIN: 133 PAD patients, 3 g/day for six months. Limitations: Endpoint-dependent pattern; not every marker necessarily decreased. Evidence access: Primary abstract L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. · 2007 · https://pubmed.ncbi.nlm.nih.gov/17592080/ · DOI 10.1161/circulationaha.106.683656
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.